Testing MB-CART19.1 therapy for severe lupus
Part of Immune system & allergy, Skin clinical trials.
This trial tests a new type of treatment called CAR T-cell therapy (MB-CART19.1) for people with severe lupus that has not responded to other treatments. It aims to see if this therapy can help control lupus and improve organ function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older
- You must have a diagnosis of SLE with major organ involvement (like kidney, heart, or lungs)
- You must have tried at least two standard lupus treatments and they didn't work well enough
- You must have a certain level of immune cells (CD3+ T cells) and be willing to use contraception for 12 months after treatment
- You must be fully vaccinated against COVID-19 or have had a confirmed infection in the last 6 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR-T cell treatment made from donor umbilical cord blood for people with lupus that hasn't improved with at least two standard treatments. The goal is to see if it can help control disease activity.
This trial tests an experimental cell therapy that targets a specific type of immune cell (B cell) to calm the overactive immune response in lupus, which may help reduce symptoms. It is for people with active lupus that has not responded well to other treatments.
This trial tests a treatment called CART19, where your own immune cells are modified in a lab to target and destroy faulty B cells that cause lupus inflammation. It's for young people with active lupus that hasn't improved with standard treatments.
This trial tests a new treatment called CD19 CAR-T cell therapy for people with severe lupus nephritis (lupus-related kidney inflammation) that hasn't improved with usual treatments. The therapy uses your own immune cells to target and possibly reset the immune system, which may reduce kidney damage and help control the disease.
This trial tests a new type of immunotherapy called CAR-T cell therapy for people with severe lupus that hasn't improved with usual treatments. The therapy uses your own immune cells to target and reduce the abnormal immune response that causes lupus symptoms.
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins on immune cells (CD19 and BCMA) to treat lupus that hasn't responded to standard treatments. It may help people with moderate to severe lupus by reducing disease activity without ongoing medication.
Hear when a new SLE - Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.